Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Co    LLY

News SummaryMost relevantAll newsSector newsTweets 

Eli Lilly & Co. : Lilly to Discontinue Late-Stage Tabalumab RA Program on Lack of Efficacy

share with twitter share with LinkedIn share with facebook
share via e-mail
02/07/2013 | 07:59pm CEST

--Lilly to discontinue rheumatoid arthritis Phase 3 program for tabalumab

--Company will take a first-quarter charge of about $50 million

--Tabalumab continues to be in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

(Updates with additional details, share movement)

   By Saabira Chaudhuri 

Eli Lilly & Co. (LLY) said it will discontinue the rheumatoid arthritis Phase 3 program for its drug, tabalumab, citing a lack of efficacy.

The announcement comes less than two months after the drug company said it would stop one of three late-stage registration studies of tabalumab due to insufficient efficacy. At the time, Lilly said it was continuing to evaluate tabalumab in two other Phase 3 rheumatoid-arthritis registration studies as well as an open-label extension study and several smaller studies.

Lilly on Thursday said it has decided to discontinue the development of tabalumab in its current rheumatoid-arthritis program based on the outcomes of two separate interim-futility analyses. All ongoing Phase 2 and Phase 3 rheumatoid-arthritis studies will be stopped.

"While we are obviously disappointed by these results in rheumatoid arthritis, we continue to believe that tabalumab could have significant potential for patients in other disease areas," said Dr. Eiry Roberts, vice president of autoimmune product development at Lilly.

The decision is expected to result in a first-quarter charge to research-and-development expenses of about $50 million.

A spokesperson for the company noted Tabalumab is still in Phase 3 development for systemic lupus, and in Phase 2 development for multiple myeloma.

The Indianapolis company is experiencing one of the steepest patent cliffs in the drug industry, grappling with recent and looming generic competition for top-selling drugs as a result of patent expirations. The company lost exclusivity for its former No. 1 product, Zyprexa, in October 2011, and it will lose U.S. patent protection for the blockbuster antidepressant Cymbalta this December.

Lilly is trying to replenish revenue lost to generic competition for the older drugs by bringing new products to market and by increasing sales of drugs that remain patent-protected.

Last month, Lilly said its fourth-quarter earnings slipped 3.6% as the drug maker recorded weaker revenue as sales of Zyprexa slid.

Shares of Lilly, which backed its view for the year, edged down 41 cents to $53.52 in recent trading. The stock has risen 36% in the past 12 months.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND CO
04/24 ELI LILLY AND : Lilly Announces Phase 3 MONARCH 3 Breast Cancer Study of Abemaci..
04/24 ELI LILLY AND : Drug Makers Stocks Under Scanner -- Bristol-Myers, AstraZeneca, ..
04/20 ELI LILLY AND : Findings in Type 2 Diabetes Reported from Eli Lilly and Company ..
04/20 ELI LILLY AND : Researchers from Eli Lilly and Company Report New Studies and Fi..
04/20 ELI LILLY AND : An Application for the Trademark "ZINLISTIQ" Has Been Filed by E..
04/20 ELI LILLY AND : Reports Summarize Organic Research Study Results from Eli Lilly ..
04/20 ELI LILLY AND : Recent Reports from Eli Lilly and Company Highlight Findings in ..
04/20 ELI LILLY AND : New Findings from Eli Lilly and Company Describe Advances in Eic..
04/20 ELI LILLY AND : Researchers at Eli Lilly and Company Release New Data on Hyperph..
04/20 ELI LILLY AND : New Findings from Eli Lilly and Company in the Area of Osteoporo..
More news
Sector news : Pharmaceuticals - NEC
12:32a Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals
04/24 J&J, Takeda among interested in Brazil's Hypermarcas, sources say
04/24DJFresenius Kabi To Strengthen And Diversify Product Portfolio By Acquiring Ako..
04/24DJMERCK : Vaunted Ebola Vaccine Faces Questions
04/24 Becton Dickinson to acquire Bard for $24 billion
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
04/24 Notable earnings before Tuesday?s open
04/24 EARNINGS PREVIEW : Lilly, Lockheed Martin, And CAT Report Tomorrow
04/24 A Physician Analyzes Valeant's Siliq, As The Stock Crashes
04/24 INCYTE : Little Upside Left
04/24 Game Plan For The Week - Cramer's Mad Money (4/21/17)
Financials ($)
Sales 2017 22 108 M
EBIT 2017 5 514 M
Net income 2017 3 688 M
Debt 2017 5 022 M
Yield 2017 2,55%
P/E ratio 2017 28,62
P/E ratio 2018 20,58
EV / Sales 2017 4,31x
EV / Sales 2018 4,21x
Capitalization 90 354 M
More Financials
Duration : Period :
Eli Lilly and Co Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Full-screen chart
Technical analysis trends ELI LILLY AND CO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 88,8 $
Spread / Average Target 8,4%
Consensus details
EPS Revisions
More Estimates Revisions
David A. Ricks President, Chief Executive Officer & Director
John C. Lechleiter Chairman
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND CO11.34%90 354
JOHNSON & JOHNSON5.69%330 078
ROCHE HOLDING LTD.8.21%217 624
PFIZER INC.3.57%200 330
NOVARTIS AG-1.08%192 857
MERCK & CO., INC.5.13%169 673
More Results